Adele M. Gulfo served as the Chief Executive Officer, Biopharma Commercial Unit for Sumitomo Pharma America from July 2023 to September 2024. She served as Chief Business and Commercial Development Officer at Sumitovant Biopharma from December 2019 to July 2023, when Sumitovant and related entities merged into Sumitomo Pharma America.
Ms. Gulfo served as Executive Vice President and Head of Global Commercial Development for Mylan N.V. (now Viatris) from January 2014 to January 2018. Before Mylan, she spent five years at Pfizer Inc. in a number of executive positions, including President and General Manager, U.S. Primary Care, and ran Commercial Operations and the Managed Markets organization across Pfizer's U.S. biopharmaceutical business. Prior to Pfizer she held executive positions at AstraZeneca Pharmaceuticals and at the Parke-Davis division of Warner-Lambert (which later merged with Pfizer), where as Senior Director, Cardiovascular Marketing she launched Lipitor, the best-selling pharmaceutical product.
She is a member of the Innovation Growth Board at Mass General Brigham and serves as a director of Battelle Memorial Institute. Ms. Gulfo holds a B.S. in Biology from Seton Hall University and an M.B.A. in Marketing from Fairleigh Dickinson University.